open access
The use of opioids in the treatment of non-neoplastic pulmonary diseases
- Department of Palliative Medicine, Debinki 2, 80-211 Gdańsk, Poland
- Klinika Alergologii i Pneumonologii GUMed
open access
Abstract
Abstract
Keywords
opioids, dyspnoea, cough, palliative care, lung disease
Title
The use of opioids in the treatment of non-neoplastic pulmonary diseases
Journal
Palliative Medicine in Practice
Issue
Article type
Review paper
Pages
118-126
Published online
2018-06-06
Page views
617
Article views/downloads
588
Bibliographic record
Palliat Med Pract 2018;12(2):118-126.
Keywords
opioids
dyspnoea
cough
palliative care
lung disease
Authors
Magdalena Renata Osowicka
Piotr Janowiak
Agnieszka Gorzewska
- Uronis HE, Currow DC, Abernethy AP. Palliative management of refractory dyspnea in COPD. Int J Chron Obstruct Pulmon Dis. 2006; 1(3): 289–304.
- Jassem E, Batura-Gabryel H, Cofta S, et al. Polskie Towarzystwo Chorób Płuc. [Reccomendation of Polish Respiratory Society for palliative care in chronic lung diseases]. Pneumonol Alergol Pol. 2012; 80(1): 41–64.
- Vigeland CL, Hughes AH, Horton MR. Etiology and treatment of cough in idiopathic pulmonary fibrosis. Respir Med. 2017; 123: 98–104.
- Vicent L, Olarte JM, Puente-Maestu L, et al. Hospital without dyspnea: rationale and design of a multidisciplinary intervention. J Geriatr Cardiol. 2016; 13(7): 625–631.
- Damps-Konstańska I, Werachowska L, Krakowiak P, et al. Acceptance of home support and integrated care among advanced COPD patients who live outside large medical centers. Appl Nurs Res. 2016; 31: 60–64.
- Mahler DA, Murray JA, Waterman LA, et al. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J. 2009; 33(4): 771–777.
- Gifford AH, Mahler DA, Waterman LA, et al. Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. COPD. 2011; 8(3): 160–166.
- Bellofiore S, Di Maria GU, Privitera S, et al. Endogenous opioids modulate the increase in ventilatory output and dyspnea during severe acute bronchoconstriction. Am Rev Respir Dis. 1990; 142(4): 812–816.
- Pattinson KTS. Opioids and the control of respiration. Br J Anaesth. 2008; 100(6): 747–758.
- Baumgärtner U, Buchholz HG, Bellosevich A, et al. High opiate receptor binding potential in the human lateral pain system. Neuroimage. 2006; 30(3): 692–699.
- Pattinson KTS, Johnson MJ. Neuroimaging of central breathlessness mechanisms. Curr Opin Support Palliat Care. 2014; 8(3): 225–233.
- von Leupoldt A, Sommer T, Kegat S, et al. Dyspnea and pain share emotion-related brain network. Neuroimage. 2009; 48(1): 200–206.
- Parshall MB, Schwartzstein RM, Adams L, et al. American Thoracic Society Committee on Dyspnea. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012; 185(4): 435–452.
- Mahler DA. Opioids for refractory dyspnea. Expert Rev Respir Med. 2013; 7(2): 123–34; quiz 135.
- Ekström M, Nilsson F, Abernethy AA, et al. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc. 2015; 12(7): 1079–1092.
- Jennings AL, Davies AN, Higgins JPT, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002; 57(11): 939–944.
- Estfan B, Mahmoud F, Shaheen P, et al. Respiratory function during parenteral opioid titration for cancer pain. Palliat Med. 2007; 21(2): 81–86.
- Clemens KE, Klaschik E. Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage. 2007; 33(4): 473–481.
- Colasanti A, Rabiner EA, Lingford-Hughes A, et al. Opioids and anxiety. J Psychopharmacol. 2011; 25(11): 1415–1433.
- Zebraski SE, Kochenash SM, Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 2000; 66(23): 2221–2231.
- Krajnik M, Jassem E, Sobanski P. Opioid receptor bronchial tree: current science. Curr Opin Support Palliat Care. 2014; 8(3): 191–199.
- Krajnik M, Podolec Z, Siekierka M, et al. Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters. J Pain Symptom Manage. 2009; 38(5): 747–757.
- Lee AL, Harrison SL, Goldstein RS, et al. Pain and its clinical associations in individuals with COPD: a systematic review. Chest. 2015; 147(5): 1246–1258.
- Belvisi MG, Hele DJ. Cough sensors. III. Opioid and cannabinoid receptors on vagal sensory nerves. Handb Exp Pharmacol. 2009(187): 63–76.
- Mahler DA, Selecky PA, Harrod CG, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010; 137(3): 674–691.
- GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2017. Pneumologie. 2017; 71(01): 9–14.
- Marciniuk DD, Goodridge D, Hernandez P, et al. Canadian Thoracic Society COPD Committee Dyspnea Expert Working Group. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011; 18(2): 69–78.
- Molassiotis A, Bailey C, Caress A, et al. Interventions for cough in cancer. Cochrane Database Syst Rev. 2010(9): CD007881.
- Wee B, Browning J, Adams A, et al. Management of chronic cough in patients receiving palliative care: review of evidence and recommendations by a task group of the Association for Palliative Medicine of Great Britain and Ireland. Palliat Med. 2012; 26(6): 780–787.
- Yancy WS, McCrory DC, Coeytaux RR, et al. Efficacy and tolerability of treatments for chronic cough: a systematic review and meta-analysis. Chest. 2013; 144(6): 1827–1838.
- Morice AH, McGarvey L, Pavord I, et al. British Thoracic Society Cough Guideline Group. Recommendations for the management of cough in adults. Thorax. 2006; 61 Suppl 1: i1–24.
- Molassiotis A, Smith J, Mazzone P, et al. Symptomatic Treatment of Cough Among Adult Patients With Lung Cancer. Chest. 2017; 151(4): 861–874.
- Życzkowska J, Wordliczek J. Podskórne i dożylne stosowanie leków przeciwbólowych w medycynie paliatywnej. Med Paliatywna w Prakt. 2010; 4: 6–13.
- De Walden-Gałuszko K, Ciałkowska-Rysz A. Medycyna paliatywna. PZWL, Warszawa 2015.
- Simon ST, Niemand AM, Benalia H, et al. Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. J Palliat Med. 2012; 15(12): 1374–1381.
- Jensen D, Alsuhail A, Viola R, et al. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage. 2012; 43(4): 706–719.
- Masood AR, Thomas SH. Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. Br J Clin Pharmacol. 1996; 41(3): 250–252.
- Davis C, Lam W, Butcher M, et al. Low systemic bioavailability of nebulized morphine: potential therapeutic role for the relief of dyspnoea. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1992: 359.
- Hung OR, Whynot SC, Varvel JR, et al. Pharmacokinetics of inhaled liposome-encapsulated fentanyl. Anesthesiology. 1995; 83(2): 277–284.
- Macleod DB, Habib AS, Ikeda K, et al. Inhaled fentanyl aerosol in healthy volunteers: pharmacokinetics and pharmacodynamics. Anesth Analg. 2012; 115(5): 1071–1077.
- Ward ME, Woodhouse A, Mather LE, et al. Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin Pharmacol Ther. 1997; 62(6): 596–609.
- Quigley C, Joel S, Patel N, et al. A phase I/II study of nebulized morphine-6-glucuronide in patients with cancer-related breathlessness. J Pain Symptom Manage. 2002; 23(1): 7–9.
- Zeppetella G. Nebulized morphine in the palliation of dyspnoea. Palliat Med. 1997; 11(4): 267–275.
- Tanaka K, Shima Y, Kakinuma R, et al. Effect of nebulized morphine in cancer patients with dyspnea: a pilot study. Jpn J Clin Oncol. 1999; 29(12): 600–603.
- Tooms A, McKenzie A, Grey H. Nebulised morphine. The Lancet. 1993; 342(8879): 1123–1124.
- Noseda A, Carpiaux JP, Markstein C, et al. Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. Eur Respir J. 1997; 10(5): 1079–1083.
- Masood AR, Reed JW, Thomas SH. Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax. 1995; 50(6): 629–634.
- Harris-Eze AO, Sridhar G, Clemens RE, et al. Low-dose nebulized morphine does not improve exercise in interstitial lung disease. Am J Respir Crit Care Med. 1995; 152(6 Pt 1): 1940–1945.
- Jankelson D, Hosseini K, Mather LE, et al. Lack of effect of high doses of inhaled morphine on exercise endurance in chronic obstructive pulmonary disease. Eur Respir J. 1997; 10(10): 2270–2274.
- Beauford W, Saylor TT, Stansbury DW, et al. Effects of nebulized morphine sulfate on the exercise tolerance of the ventilatory limited COPD patient. Chest. 1993; 104(1): 175–178.
- Leung R, Hill P, Burdon J. Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax. 1996; 51(6): 596–600.
- Young IH, Daviskas E, Keena VA. Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax. 1989; 44(5): 387–390.
- Shohrati M, Ghanei M, Harandi AA, et al. Effect of nebulized morphine on dyspnea of mustard gas-exposed patients: a double-blind randomized clinical trial study. Pulm Med. 2012; 2012: 610921.
- Bruera E, Sala R, Spruyt O, et al. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage. 2005; 29(6): 613–618.
- Farncombe M, Chater S, Gillin A. The use of nebulized opioids for breathlessness: a chart review. Palliat Med. 1994; 8(4): 306–312.
- Farncombe M, Chater S. Case studies outlining use of nebulized morphine for patients with end-stage chronic lung and cardiac disease. J Pain Symptom Manage. 1993; 8(4): 221–225.
- Farncombe M, Chater S. Clinical application of nebulized opioids for treatment of dyspnoea in patients with malignant disease. Support Care Cancer. 1994; 2(3): 184–187.
- Cohen SP, Dawson TC. Nebulized morphine as a treatment for dyspnea in a child with cystic fibrosis. Pediatrics. 2002; 110(3): e38.
- Janahi IA, Maciejewski SR, Teran JM, et al. Inhaled morphine to relieve dyspnea in advanced cystic fibrosis lung disease. Pediatr Pulmonol. 2000; 30(3): 257–259.
- Davis C, Penn K, et al. A’Hern R, Single dose randomised controlled trial of nebulised morphine in patients with cancer related breathlessness. Palliat Med. 1996; 10: 64–65.
- Davis C, Hodder C, Love S, et al. Effect of nebulised morphine and morphine-6-glucuronide on exercise endurance in patients with chronic obstructive pulmonary disease. Thorax. 1994; 49: 393.
- Sarhill N, Walsh D, Khawam E, et al. Nebulized hydromorphone for dyspnea in hospice care of advanced cancer. Am J Hosp Palliat Care. 2000; 17(6): 389–391.
- Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage. 2008; 36(1): 29–38.
- Graff GR, Stark JM, Grueber R. Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient. Respiration. 2004; 71(6): 646–649.
- Coyne P, Viswanathan R, Smith T. Nebulized Fentanyl Citrate Improves Patients' Perception of Breathing, Respiratory Rate, and Oxygen Saturation in Dyspnea. Journal of Pain and Symptom Management. 2002; 23(2): 157–160.
- Kallet RH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care. 2007; 52(7): 900–910.
- Barnes H, McDonald J, Smallwood N, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016; 3: CD011008.
- Janowiak P, Krajnik M, Podolec Z, et al. Dosimetrically administered nebulized morphine for breathlessness in very severe chronic obstructive pulmonary disease: a randomized, controlled trial. BMC Pulm Med. 2017; 17(1): 186.
- Rutherford RM, Azher T, Gilmartin JJ. Dramatic response to nebulized morphine in an asthmatic patient with severe chronic cough. Ir Med J. 2002; 95(4): 113–114.
- Stein WM, Min YK. Nebulized morphine for paroxysmal cough and dyspnea in a nursing home resident with metastatic cancer. Am J Hosp Palliat Care. 1997; 14(2): 52–56.
- An HoJ, Kim IK, Lee JE, et al. Nebulized morphine for intractable cough in advanced cancer: two case reports. J Palliat Med. 2015; 18(3): 278–281.
- Viola R, Bak K, Cathy K, et al. Cancer Care Ontario’s Symptom Management Guide-to-Practice: Dyspnoea. 2017.
- Hui D, Xu A, Frisbee-Hume S, et al. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. J Pain Symptom Manage. 2014; 47(2): 209–217.
- Hui D, Kilgore K, Park M, et al. Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial. J Pain Symptom Manage. 2016; 52(4): 459–468.e1.
- Hui D, Kilgore K, Frisbee-Hume S, et al. Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial. J Pain Symptom Manage. 2017; 54(6): 798–805.
- Simon ST, Kloke M, Alt-Epping B, et al. EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. J Pain Symptom Manage. 2016; 52(5): 617–625.
- Juan G, Ramón M, Valia JC, et al. Palliative treatment of dyspnea with epidural methadone in advanced emphysema. Chest. 2005; 128(5): 3322–3328.
- Shinjo T, Okada M. [Efficacy of controlled-release oxycodone for dyspnea in cancer patients--three case series]. Gan To Kagaku Ryoho. 2006; 33(4): 529–532.
- Tanaka M, Maeba H, Senoo T, et al. Efficacy of Oxycodone for Dyspnea in End-stage Heart Failure with Renal Insufficiency. Intern Med. 2018; 57(1): 53–57.
- Gajewski P, Szczeklik A. Interna Szczeklika. Medycyna Praktyczna, Kraków 2017.
- Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011; 42(3): 388–399.
- Booth S, Bausewein C, Higginson I, et al. Pharmacological treatment of refractory breathlessness. Expert Rev Respir Med. 2009; 3(1): 21–36.
- Varkey B. Opioids for palliation of refractory dyspnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med. 2010; 16(2): 150–154.
- Leppert W. The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities. Contemp Oncol (Pozn). 2012; 16(2): 125–131.
- Yamanaka T, Sadikot RT. Opioid effect on lungs. Respirology. 2013; 18(2): 255–262.
- Cheatle MD, Webster LR. Opioid Therapy and Sleep Disorders: Risks and Mitigation Strategies. Pain Med. 2015; 16 Suppl 1: S22–S26.
- Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage. 2002; 23(4): 278–291.
- Baldo BA, Pham NH. Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two. Anaesth Intensive Care. 2012; 40(2): 216–235.
- Webster LR. Eight principles for safer opioid prescribing. Pain Med. 2013; 14(7): 959–961.
- Parmar MS. Exacerbation of asthma secondary to fentanyl transdermal patch. BMJ Case Rep. 2009; 2009.
- Gaspar C, Alfarroba S, Telo L, et al. End-of-life care in COPD: a survey carried out with Portuguese pulmonologists. Rev Port Pneumol. 2014; 20(3): 123–130.
- Rocker G, Young J, Horton R. USING OPIOIDS TO TREAT DYSPNEA IN ADVANCED COPD: A SURVEY OF CANADIAN CLINICIANS. Chest. 2008; 134(4).
- Janssen DJA, de Hosson SM, bij de Vaate E, et al. Attitudes toward opioids for refractory dyspnea in COPD among Dutch chest physicians. Chron Respir Dis. 2015; 12(2): 85–92.
- Ekström MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014; 348: g445.
- Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2016; 48(3): 683–693.
- Neutel CI, Johansen HL. Association between hypnotics use and increased mortality: causation or confounding? Eur J Clin Pharmacol. 2015; 71(5): 637–642.
- Thorns A, Sykes N. Opioid use in last week of life and implications for end-of-life decision-making. Lancet. 2000; 356(9227): 398–399.
- Chan JD, Treece PD, Engelberg RA, et al. Narcotic and benzodiazepine use after withdrawal of life support: association with time to death? Chest. 2004; 126(1): 286–293.